Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly’s blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

1. PharmaPoint: Osteoporosis – Global Drug Forecast and
Market Analysis to 2022
by
GlobalData
Explore all reports for “Osteoporosis Drugs” market
@
http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/diseases-treatment/osteoporosisdrugs .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

2. PharmaPoint: Osteoporosis – Global Drug
Forecast and Market Analysis to 2022
Despite its maturity, the osteoporosis market is expected to undergo substantial
change between 2012 and 2022. Most importantly, the ‘ gold-standard’
bisphosphonates will lose patent protection by end-of-year 2013, flooding the
marketplace with less expensive generic versions of these physician-preferred
medications. Additionally, Eli Lilly’s blockbuster Evista, the only available SERM in the
US, will lose patent protection in 2014, flooding the market with yet more affordable
generic options. Also during the forecast period covered by this report, osteoporosis
drug development research will lead to the launches of a wave of novel anabolic
drugs with greater efficacy and safety, causing a major market shift away from antiresorptive drugs. The number of companies vying for patient share will shrink by as
much as 50%, as established players exit the market or acquire smaller players. Lastly,
the aging of the population in developed markets will result in a larger patient pool.
These changes in the osteoporosis market will be reflected in the slow growth during
the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD
at a CAGR of 3%.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150335 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

3. PharmaPoint: Osteoporosis – Global Drug
Forecast and Market Analysis to 2022
Key Questions Answered
•Bisphosphonates and selective estrogen receptor modulators (SERMs)
dominate the osteoporosis market. However, unmet needs exist in terms of
safety and efficacy. Will the drugs under development fulfill the unmet needs of
the osteoporosis market?
•Six major brands are due to lose patent protection before 2015. How will these
patent expiries as well as new product launches impact the osteoporosis
therapeutics market?
•The developmental pipeline consists of several novel drugs. Which of these
drugs will attain high sales revenues during 2012-2022? Which will have the
highest peak sales at the highest CAGR, and why?
•The osteoporosis patient population in the targeted geographies will increase
marginally from 2012-2012 with the increase of the overall disease population.
How will epidemiological changes impact the growth of the future market?
Complete report available @
http://www.rnrmarketresearch.com/pharmapoint-osteoporosis-globaldrug-forecast-and-market-analysis-to-2022-market-report.html .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

4. PharmaPoint: Osteoporosis – Global Drug
Forecast and Market Analysis to 2022
Scope
•Overview of osteoporosis, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines.
•Annualized osteoporosis therapeutics market revenue, annual cost of therapy
and treatment usage pattern data 2012 and forecast for ten years to 2022.
•Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and implications for the
osteoporosis therapeutics market.
•Pipeline analysis: comprehensive data split across different phases, emerging
trends and mechanisms of action under development, including anti-sclerostin
antibodies, cathepsin K inhibitors, SERMs with conjugated estrogens, and
human parathyroid hormone related protein.
•Analysis of the current and future market competition in the global
osteoporosis therapeutics market. Insightful review of the key industry drivers,
restraints and challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150335 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

5. PharmaPoint: Osteoporosis – Global Drug
Forecast and Market Analysis to 2022
Reasons to buy
•Develop and design your in-licensing and out-licensing strategies through a review
of pipeline products and technologies, and by identifying the companies with the
most robust pipeline. Additionally a list of acquisition targets included in the pipeline
product company list.
•Develop business strategies by understanding the trends shaping and driving the
global osteoporosis therapeutics market.
•Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the global
osteoporosis therapeutics market in future.
•Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
•Identify emerging players with potentially strong product portfolios and create
effective counter-strategies to gain a competitive advantage.
•Track drug sales in the global osteoporosis therapeutics market from 2012-2022.
•Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and
strategic partnerships.
Request sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=150335 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

6. PharmaPoint: Osteoporosis – Global Drug
Forecast and Market Analysis to 2022
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com /
+18883915441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441